Medtronic plc Q1 FY2027 results
$102.86+1.85%
Medtronic plc reported revenue of $9.76 billion, up 13.7% from a year earlier, net income of $1.47 billion and diluted earnings per share of $1.14 against $0.81 for the first quarter of fiscal 2027 (the three months to 31 Jul 2026).
From its quarterly report, the results first announced on 1 Sep 2026. Compiled and checked by AapWire.
Q1 FY2027 against Q1 FY2026
Three months to 31 Jul 2026, against the three months to 25 Jul 2025. Amounts in USD.
| Measure | Q1 FY2027 | Q1 FY2026 | Change |
|---|---|---|---|
| Revenue | $9.76B | $8.58B | +13.7% |
| Gross profit | $6.34B | $5.58B | +13.7% |
| Gross margin | 65.0% | 65.0% | −0.0 pts |
| Operating income | $1.76B | $1.45B | +22.1% |
| Operating margin | 18.1% | 16.8% | +1.2 pts |
| Net income | $1.47B | $1.04B | +41.3% |
| Diluted EPS | $1.14 | $0.81 | +40.7% |
| Operating cash flow | $1.79B | $1.09B | +64.8% |
| Capital expenditure | $503.0M | $504.0M | −0.2% |
| Free cash flow | $1.29B | $584.0M | +121% |
Operating KPIs for the quarter
| KPI | Q1 FY2027 | Change on a year |
|---|---|---|
| Electrophysiology Therapies revenue | $2.2B | up 29.6% |
| Surgical & Endoscopy revenue | $1.7B | up 8.7% |
| Cranial & Spinal Technologies revenue | $1.4B | up 12.7% |
| Specialty Therapies revenue | $774.0M | up 10.3% |
| Acute Care & Monitoring revenue | $539.0M | up 14.4% |
| Neuromodulation revenue | $539.0M | up 4.9% |
| Reportable segment net sales | $8.9B | up 14.1% |
| Cardiovascular revenue | $3.9B | up 19.5% |
| Neuroscience revenue | $2.7B | up 10.3% |
| Medical Surgical revenue | $2.3B | up 9.9% |
| Diabetes revenue | $843.0M | up 16.9% |
| United States revenue | $4.9B | up 16.1% |
| International revenue | $4.9B | up 11.4% |
| Rest of world revenue | $4.8B | up 11.3% |
| Ireland revenue | $40.0M | up 21.2% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q1 FY2027 | 31 Jul 2026 | $9.76B | +13.7% | $1.14 |
| Q4 FY2026 | 24 Apr 2026 | $9.81B | +9.9% | $0.97 |
| Q3 FY2026 | 23 Jan 2026 | $9.02B | +8.7% | $0.89 |
| Q2 FY2026 | 24 Oct 2025 | $8.96B | +6.6% | $1.07 |
| Q1 FY2026 | 25 Jul 2025 | $8.58B | +8.4% | $0.81 |
| Q4 FY2025 | 25 Apr 2025 | $8.93B | +3.9% | $0.82 |
| Q3 FY2025 | 24 Jan 2025 | $8.29B | +2.5% | $1.01 |
| Q2 FY2025 | 25 Oct 2024 | $8.40B | +5.2% | $0.99 |
More on Medtronic plc: financial statements · revenue · earnings per share
MDT's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
